October 28, 2021 7:42am
After a seven (7) sector stumbles out of eight (8) sessions, the probabilities of some upside are still relative yet, the aftermarket was very slim
Earnings: Alnylam Pharmaceuticals (ALNY) and has News: the HELIOS-A P3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis, met all secondary endpoints measured at 18 months.
Pre-open indications: 5 SELLs with 1 Pump (or No Promote)
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.25 % (+89 points), S&P futures are UP +0.31% (+14 point) and NASDAQ futures are UP +0.55% (+86 point)
Stock futures edged higher in premarket trading Thursday,
European stocks were mixed waiting fora rate decision by the European Central Bank.
Asia pacific stocks were lower as the Bank of Japan announced its decision to hold steady on monetary policy.
Henry’omics:
On Wednesday, the S&P 500 slipped 0.5% for its first down day in three as the Dow dipped -0.74% falling for the first time in four days while the Nasdaq cruised to a flat close.
The S&P 500 has gained +5.6%, the Dow is up +4.9% and the Nasdaq has accelerated +5.5% in October.
Note: Merck (MRK +$1.98 or +2.43% to $83.52) saw its shares rise pre-market after the company posted with earnings beat on the top and bottom lines.
If you didn’t remember what happen at Wednesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
- Wednesday’s evening’s recap: “the market and sector symbolize a game of “chutes and ladders” of ups and downs. The question revolves around what is determined to be the “spinner” in these markets.” … https://www.regmedinvestors.com/articles/12157
Q4: October, 7 positive and 12 negative closes
Q3/21:
- September, 1 holiday, 10 positive and 10 negative close
- August - 12 positive and 10 negative close
- July: 6 positives, 1 holiday and 15 negative closes
Companies in my headlights – It’s your decision; I provide an idea and context:
SELL with a Pump or no promote:
Biostage (BSTG) closed up +$0.10 after being down -$0.40 with 216 shares traded when suddenly 1,676 shares traded following Tuesday’s -$0.05 with 1,216 shares traded after Monday’s flat at $3.05 with 609 shares traded, Friday’s -$0.156 with 516 shares traded, Thursday’s -$0.095 with 265 shares traded, and last Wednesday’s +$0.30 with 8,356 shares traded.
- For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.
- What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?
Maintaining SELL and profit:
bluebird bio (BLUE) closed up +$1.11 to $222.06 after Tuesday’s -$0.28 to $20.95, Monday’s +$0.43, Friday’s +$0.41 to $20.80 and last Thursday’s -$0.59 with a positive -$0.08 or -0.36% pre-open indication as Zacks estimates to an expected to post quarterly loss of $2.72 per share in its upcoming report, which represents a year-over-year change of +7.5%. Revenues are expected to be $55.81 million, up 189.6% from Q3/20.
Intellia Therapeutics (NTLA) closed down -$2.40 to $129.60 with a positive +$0.40 or +0.31% aftermarket indication; also, with a 52-week change of +440.98%.
Mesoblast (MESO) closed down again -$0.18 to $6.06 after Tuesday’s -$0.06 to $6.24 with a negative -$0.06 or -0.99% aftermarket indication.
BioLife Solutions (BLFS) closed up again +$1.23 to $48.50 after Tuesday’s +$1.99 to $47.27, Monday’s +$2.28 to $45.28, Friday’s +$0.01 and last Thursday’s +$0.54 with a +$1.35 or +2.78% pre-open indication with a 52-week change of +62.55%.
Global Blood Therapeutics (GBT) closed up +$2.78 to $32.78 with a positive +$0.45 to +1.37% aftermarket indication.
The BOTTOM LINE: Reiterating, “Don't let earnings week take advantage of you” … because it will!
Be ready to act on up-coming earnings news, good or bad, but don't be too hasty.
It's highly risky to buy a stock just before earnings, and investors may want to take whole or partial profits on holdings with tiny gains.
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
The stem, cell and gene therapy earnings with Sage Therapeutics (SAGE), Ultragenyx Pharmaceuticals (RARE) and Regenxbio (RGNX) on 11/2, Editas Medicine (EDIT) on 11/8, Vericel (VCEL) on 11/9, Athersys (ATHX) and Brainstorm Cell Therapeutics (BCLI) coming 11/15 (to date).
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
